Drug Profile
WIN 552122
Alternative Names: WIN 55212; WIN 55212-2Latest Information Update: 20 Feb 2006
Price :
$50
*
At a glance
- Originator Sanofi Winthrop
- Developer Sanofi Winthrop; University of Minnesota
- Class Antiparkinsonians; Cannabinoids; Neuroprotectants
- Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma; Movement disorders; Neurological disorders; Pain
Most Recent Events
- 20 Feb 2006 Discontinued - Preclinical for Glaucoma in USA (Ophthalmic)
- 20 Feb 2006 Discontinued - Preclinical for Movement disorders in USA (unspecified route)
- 20 Feb 2006 Discontinued - Preclinical for Neurological disorders in Spain (unspecified route)